GKIM
BBIO icon

GW&K Investment Management’s BridgeBio Pharma BBIO Stock Holding History

GW&K Investment Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$71.5M Buy
962,643
+336,521
+54% +$24.4M 0.63% 36
2025
Q4 		$47.9M Buy
626,122
+27,885
+5% +$1.83M 0.41% 89
2025
Q3 		$31.1M Buy
+598,237
New +$29.2M 0.27% 141

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GW&K Investment Management's BBIO Position: Q1 2026 in Review

GW&K Investment Management increased its BridgeBio Pharma (BBIO) stake by 54% in Q1 2026, buying an estimated $24.4M and bringing the position to 962,643 shares worth $71.5M. The position accounts for 0.63% of the portfolio, ranked #36.

GW&K Investment Management first reported a position in BBIO in Q3 2025 and has held it in 3 quarters since. 458 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • GW&K Investment Management held 962,643 shares of BridgeBio Pharma worth $71.5M as of Q1 2026.
  • GW&K Investment Management bought 336,521 BridgeBio Pharma shares in Q1 2026, an estimated $24.4M.
  • BridgeBio Pharma made up 0.63% of GW&K Investment Management's portfolio in Q1 2026, its #36 holding.
  • GW&K Investment Management first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 3 quarters since.
  • 458 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on GW&K Investment Management's 13F filing for Q1 2026, filed 13 May 2026.